Laura Chico
Stock Analyst at Wedbush
(1.99)
# 1,594
Out of 4,412 analysts
144
Total ratings
33.33%
Success rate
-7.32%
Average return
Main Sectors:
30 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Neutral | $213 → $215 | $208.90 | +2.92% | 12 | Apr 25, 2024 | |
| TVTX Travere Therapeutics | Reiterates: Outperform | $13 | $5.26 | +147.15% | 7 | Apr 17, 2024 | |
| SAGE Sage Therapeutics | Reiterates: Neutral | $24 | $13.69 | +75.31% | 5 | Apr 17, 2024 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Neutral | $48 | $44.24 | +8.50% | 7 | Apr 17, 2024 | |
| NBIX Neurocrine Biosciences | Reiterates: Outperform | $147 | $135.99 | +8.10% | 6 | Apr 17, 2024 | |
| ARDX Ardelyx | Maintains: Outperform | $13 → $14 | $6.42 | +118.07% | 9 | Apr 17, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $67 → $57 | $49.86 | +14.32% | 11 | Apr 17, 2024 | |
| EWTX Edgewise Therapeutics | Reiterates: Outperform | $26 | $16.17 | +60.79% | 6 | Apr 16, 2024 | |
| RLYB Rallybio | Maintains: Outperform | $13 → $11 | $1.70 | +547.06% | 4 | Apr 11, 2024 | |
| PHVS Pharvaris | Reiterates: Outperform | $35 | $23.35 | +49.89% | 4 | Apr 11, 2024 | |
| GOSS Gossamer Bio | Assumes: Outperform | $4 | $0.67 | +498.80% | 1 | Apr 5, 2024 | |
| OVID Ovid Therapeutics | Initiates: Outperform | $8 | $3.10 | +158.06% | 1 | Apr 5, 2024 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $13 → $17 | $12.41 | +36.99% | 5 | Mar 26, 2024 | |
| ATXS Astria Therapeutics | Maintains: Outperform | $17 | $9.00 | +88.89% | 6 | Mar 26, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $24 → $33 | $21.50 | +53.49% | 3 | Mar 22, 2024 | |
| VERA Vera Therapeutics | Maintains: Neutral | $21 → $34 | $39.65 | -14.25% | 6 | Mar 21, 2024 | |
| DSGN Design Therapeutics | Reiterates: Neutral | $5 | $3.78 | +32.28% | 5 | Mar 20, 2024 | |
| LBPH Longboard Pharmaceuticals | Reiterates: Outperform | $32 | $19.72 | +62.27% | 4 | Mar 13, 2024 | |
| PEPG PepGen | Maintains: Outperform | $21 → $20 | $11.93 | +67.64% | 6 | Mar 7, 2024 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $46 → $51 | $40.50 | +25.93% | 6 | Mar 1, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $39 → $40 | $12.88 | +210.56% | 6 | Feb 28, 2024 | |
| DNLI Denali Therapeutics | Reiterates: Outperform | $31 | $15.43 | +100.91% | 5 | Feb 28, 2024 | |
| PRAX Praxis Precision Medicines | Maintains: Neutral | $16 → $29 | $54.80 | -47.08% | 5 | Jan 12, 2024 | |
| VIGL Vigil Neuroscience | Reiterates: Outperform | $23 | $2.71 | +748.71% | 4 | Nov 17, 2023 | |
| BMRN BioMarin Pharmaceutical | Initiates: Market Perform | n/a | $80.91 | - | 4 | Sep 28, 2023 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $9 → $5 | $2.39 | +109.21% | 2 | Aug 12, 2022 | |
| BHVN Biohaven Pharmaceutical Holding Company | Downgrades: Neutral | $149 | $38.97 | +281.06% | 1 | Aug 8, 2022 | |
| VYGR Voyager Therapeutics | Downgrades: Neutral | n/a | $7.62 | - | 1 | Feb 3, 2021 | |
| CRBP Corbus Pharmaceuticals Holdings | Initiates: Outperform | n/a | $34.25 | - | 1 | Jan 19, 2018 | |
| CDTX Cidara Therapeutics | Initiates: Strong Buy | $280 | $12.63 | +2,116.94% | 1 | Apr 21, 2017 |
Biogen
Apr 25, 2024
Maintains: Neutral
Price Target: $213 → $215
Current: $208.90
Upside: +2.92%
Travere Therapeutics
Apr 17, 2024
Reiterates: Outperform
Price Target: $13
Current: $5.26
Upside: +147.15%
Sage Therapeutics
Apr 17, 2024
Reiterates: Neutral
Price Target: $24
Current: $13.69
Upside: +75.31%
Ultragenyx Pharmaceutical
Apr 17, 2024
Reiterates: Neutral
Price Target: $48
Current: $44.24
Upside: +8.50%
Neurocrine Biosciences
Apr 17, 2024
Reiterates: Outperform
Price Target: $147
Current: $135.99
Upside: +8.10%
Ardelyx
Apr 17, 2024
Maintains: Outperform
Price Target: $13 → $14
Current: $6.42
Upside: +118.07%
Apellis Pharmaceuticals
Apr 17, 2024
Maintains: Neutral
Price Target: $67 → $57
Current: $49.86
Upside: +14.32%
Edgewise Therapeutics
Apr 16, 2024
Reiterates: Outperform
Price Target: $26
Current: $16.17
Upside: +60.79%
Rallybio
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $1.70
Upside: +547.06%
Pharvaris
Apr 11, 2024
Reiterates: Outperform
Price Target: $35
Current: $23.35
Upside: +49.89%
Gossamer Bio
Apr 5, 2024
Assumes: Outperform
Price Target: $4
Current: $0.67
Upside: +498.80%
Ovid Therapeutics
Apr 5, 2024
Initiates: Outperform
Price Target: $8
Current: $3.10
Upside: +158.06%
Stoke Therapeutics
Mar 26, 2024
Maintains: Outperform
Price Target: $13 → $17
Current: $12.41
Upside: +36.99%
Astria Therapeutics
Mar 26, 2024
Maintains: Outperform
Price Target: $17
Current: $9.00
Upside: +88.89%
Dianthus Therapeutics
Mar 22, 2024
Maintains: Outperform
Price Target: $24 → $33
Current: $21.50
Upside: +53.49%
Vera Therapeutics
Mar 21, 2024
Maintains: Neutral
Price Target: $21 → $34
Current: $39.65
Upside: -14.25%
Design Therapeutics
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $3.78
Upside: +32.28%
Longboard Pharmaceuticals
Mar 13, 2024
Reiterates: Outperform
Price Target: $32
Current: $19.72
Upside: +62.27%
PepGen
Mar 7, 2024
Maintains: Outperform
Price Target: $21 → $20
Current: $11.93
Upside: +67.64%
Xenon Pharmaceuticals
Mar 1, 2024
Maintains: Outperform
Price Target: $46 → $51
Current: $40.50
Upside: +25.93%
Viridian Therapeutics
Feb 28, 2024
Maintains: Outperform
Price Target: $39 → $40
Current: $12.88
Upside: +210.56%
Denali Therapeutics
Feb 28, 2024
Reiterates: Outperform
Price Target: $31
Current: $15.43
Upside: +100.91%
Praxis Precision Medicines
Jan 12, 2024
Maintains: Neutral
Price Target: $16 → $29
Current: $54.80
Upside: -47.08%
Vigil Neuroscience
Nov 17, 2023
Reiterates: Outperform
Price Target: $23
Current: $2.71
Upside: +748.71%
BioMarin Pharmaceutical
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $80.91
Upside: -
Taysha Gene Therapies
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $2.39
Upside: +109.21%
Biohaven Pharmaceutical Holding Company
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $38.97
Upside: +281.06%
Voyager Therapeutics
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $7.62
Upside: -
Corbus Pharmaceuticals Holdings
Jan 19, 2018
Initiates: Outperform
Price Target: n/a
Current: $34.25
Upside: -
Cidara Therapeutics
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $12.63
Upside: +2,116.94%